Literature DB >> 23606937

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Claire Harrison1, Alessandro M Vannucchi.   

Abstract

Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012. Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently. In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.

Entities:  

Keywords:  JAKafi; janus kinase 2; myelofibrosis; myeloproliferative neoplasm; ruxolitinib

Year:  2012        PMID： 23606937      PMCID： PMC3627327          DOI： 10.1177/2040620712459746

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  71 in total

1.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Authors:  R Jäger; H Gisslinger; F Passamonti; E Rumi; T Berg; B Gisslinger; D Pietra; A Harutyunyan; T Klampfl; D Olcaydu; M Cazzola; R Kralovics
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 11.528

2.  Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).

Authors:  Jian-kang Jiang; Kamran Ghoreschi; Francesca Deflorian; Zhi Chen; Melissa Perreira; Marko Pesu; Jeremy Smith; Dac-Trung Nguyen; Eric H Liu; William Leister; Stefano Costanzi; John J O'Shea; Craig J Thomas
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

3.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Authors:  Giovanni Barosi; Gunnar Birgegard; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.

Authors:  Ruben A Mesa; Hagop Kantarjian; Ayalew Tefferi; Amylou Dueck; Richard Levy; Kris Vaddi; Susan Erickson-Viitanen; Deborah A Thomas; Jorge Cortes; Gautam Borthakur; Animesh D Pardanani; Zeev Estrov; Srdan Verstovsek
Journal:  Cancer       Date:  2011-04-08       Impact factor: 6.860

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

8.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

9.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

10.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528
View more
  16 in total

1.  Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells.

Authors:  Kimberly M Arnold; Lynn M Opdenaker; Nicole J Flynn; Daniel Kwesi Appeah; Jennifer Sims-Mourtada
Journal:  Int J Radiat Biol       Date:  2020-01-06       Impact factor: 2.694

2.  Imatinib and ruxolitinib association: first experience in two patients.

Authors:  Alessandra Iurlo; Umberto Gianelli; Davide Rapezzi; Daniele Cattaneo; Elisa Fermo; Francesca Binda; Elisa Santambrogio; Cristina Bucelli; Agostino Cortelezzi
Journal:  Haematologica       Date:  2014-03-14       Impact factor: 9.941

3.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

Review 4.  [Biobanking requirements from the perspective of the clinician : Experiences in hematology and oncology].

Authors:  S Koschmieder; T H Brümmendorf
Journal:  Pathologe       Date:  2018-07       Impact factor: 1.011

5.  Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.

Authors:  B Melosky; S Banerji; N Blais; Q Chu; R Juergens; N B Leighl; G Liu; P Cheema
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

6.  Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.

Authors:  Lena J McLaughlin; Lora Stojanovic; Aksinija A Kogan; Julia L Rutherford; Eun Yong Choi; Ray-Whay Chiu Yen; Limin Xia; Ying Zou; Rena G Lapidus; Stephen B Baylin; Michael J Topper; Feyruz V Rassool
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-10       Impact factor: 11.205

Review 7.  Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL).

Authors:  Manisha Agarwal; Rachna Seth; Tathagata Chatterjee
Journal:  Indian J Hematol Blood Transfus       Date:  2020-06-03       Impact factor: 0.900

8.  Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C-/- mice.

Authors:  Shirin Hasan; Liping Hu; Olatundun Williams; Elizabeth A Eklund
Journal:  Exp Hematol       Date:  2022-03-09       Impact factor: 3.084

9.  A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives.

Authors:  Yi Li; Lina Wei; Marie-Charlotte Meinsohn; Rana Suliman; Maeva Chauvin; Jim Berstler; Kate Hartland; Mark M Jensen; Natalie A Sicher; Nicholas Nagykery; Patricia K Donahoe; David Pepin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-05       Impact factor: 12.779

Review 10.  Ruxolitinib in Myelofibrosis and Polycythemia Vera.

Authors:  Leah Wolfe
Journal:  J Adv Pract Oncol       Date:  2016-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.